Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity

Progress in cytokine engineering is driving therapeutic translation by overcoming the inherent limitations of these proteins as drugs. The interleukin-2 (IL-2) cytokine harbors great promise as an immune stimulant for cancer treatment. However, the cytokine’s concurrent activation of both pro-inflam...

Descripción completa

Detalles Bibliográficos
Autores principales: Leonard, Elissa K., Tomala, Jakub, Gould, Joseph R., Leff, Michael I., Lin, Jian-Xin, Li, Peng, Porter, Mitchell J., Johansen, Eric R., Thompson, Ladaisha, Cao, Shanelle D., Henclova, Tereza, Huliciak, Maros, Vaněk, Ondřej, Kovar, Marek, Leonard, Warren J., Spangler, Jamie B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187205/
https://www.ncbi.nlm.nih.gov/pubmed/37205604
http://dx.doi.org/10.1101/2023.05.03.539272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187205/
https://www.ncbi.nlm.nih.gov/pubmed/37205604
http://dx.doi.org/10.1101/2023.05.03.539272

Ejemplares similares